03:16 PM EST - Revive Therapeutics Ltd. : Today announced positive final results from its phase 2a proof-of-concept clinical study of REV-002 (Bucillamine), an oral anti-inflammatory agent, for the treatment of acute gout flares. Revive Therapeutics Ltd.
shares V.RVV are trading unchanged at $0.70.
